Printer Friendly
The Free Library
23,403,340 articles and books


Mark Hofer Esq. Joins PsychoGenics as General Counsel.

HAWTHORNE, N.Y. -- PsychoGenics Inc. a private biopharmaceutical company, with expertise in the field of behavioral neuro biology, and provider CNS drug discovery solutions to Pharmaceutical and Biotechnology companies, announces that Mark Hofer, Esq. has joined the Company as General Counsel taking a partial leave of absence to do so from Brown Rudnick Berlack & Israels, a general practice law firm headquartered in Boston with offices in New England, New York and London, where he headed the Firms biotech intellectual property group.

Prior to joining the Brown Rudnick Berlack & Israels, Mr. Hofer served as Senior Vice President, General Counsel and then Chief Patent Counsel for Genzyme Corporation. Previous to that he was Chief Patent Counsel for Integrated Genetics and Patent Counsel for Johnson & Johnson. He has a bachelor's degree in Biology/Microbiology, a master's degree in Biomedical Engineering and a doctorate in Jurisprudence. He has published and lectured extensively on various intellectual property issues before many organizations and law schools, including the Harvard Law School, in the United States and Europe.

"Mark has extensive experience with biotechnology and pharmaceutical companies. He has devoted much of his work to assisting clients to identify and implement strategies for optimizing market opportunities within the context of a complex patent environment," said Emer Leahy, Ph.D., President and CEO. "We are very fortunate to have Mark on our team. He is a very creative thinker with a track record of outstanding contribution to the companies he represents. Here at PsychoGenics, Mark will play a leading role in business and patent development activities."

About PsychoGenics:

PsychoGenics, a private biopharmaceutical company, with expertise in the field of behavioral neurobiology, and provider CNS drug discovery solutions to Pharmaceutical and Biotechnology companies, is combining its expertise in behavioral neurobiology with the power of bioinformatics to develop a breakthrough, in vivo preclinical behavioral testing platform. This automated and computerized high-throughput platform offers companies an alternative approach to target discovery and validation, and drug discovery by providing faster, more objective and higher quality results than traditional, subjective manual approaches.

MAKE YOUR OPINION COUNT - Click Here http://tbutton.prnewswire.com/prn/11690X63111285

Contact: Bill Fasnacht, CFO - COO of PsychoGenics Inc., +1-914-593-0640, ext. 3003, bill.fasnacht@psychogenics.com

Website: http://www.psychogenics.com/
COPYRIGHT 2002 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2002 Gale, Cengage Learning. All rights reserved.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Comment:Mark Hofer Esq. Joins PsychoGenics as General Counsel.
Publication:PR Newswire
Geographic Code:1USA
Date:Jun 11, 2002
Words:370
Previous Article:CREF Resolution Garners Strong Support From American Power Conversion Shareholders; Greater Board Independence Urged.
Next Article:The Scholastic Art & Writing Awards Announce 2002 National Student Winners.



Related Articles
BIOGEN APPOINTS THOMAS BUCKNUM, ESQ.
PsychoGenics Inc. Names Mark Klitenick Vice President, Behavioral Operations.
PsychoGenics Obtains Funding for Their High Throughput CNS Drug Discovery Platform.
PsychoGenics Inc. Names Frederique Menzaghi, Ph.D. Vice President, External Scientific Affairs.
PsychoGenics Inc. Names Melvyn P. Heyes, Ph.D. Vice President, Preclinical Research.
Brinks Hofer Gilson & Lione Hosts Seminar for Biotech Entrepreneurs and Growing Companies.
PsychoGenics Appoints Rusiko Bourtchouladze, Ph.D., as Vice President, Cognition and Discovery Research.
PsychoGenics Announces the Launch of Psylin Neurosciences, Inc. in Partnership with Amylin Pharmaceuticals.
Psylin Neurosciences Commences Development of Compound for Depression.

Terms of use | Copyright © 2014 Farlex, Inc. | Feedback | For webmasters